October 15, 2018 (Vol. 38, No. 18)
Axol
These human induced pluripotent stem cell (hiPSC)-derived atrial cardiomyocytes can be used to develop therapeutics for cardiovascular diseases. Generated from the same donor as highly validated hiPSC-derived ventricular cardiomyocytes, this physiologically relevant hiPSC-derived cell line is quick and easy to use, ready in just seven days from thaw, for electrophysiology, cardiac contractility study, screening, and the investigation of cardiomyopathies. These hiPSC-derived atrial cardiomyocytes express typical targets, ion channels, and currents (Kv1.5, Ikir3.x, Ikur, IKACh, MLC2a, and ANP) essential for the screening of cross-target effects, the development of atrial specific target drugs, and the investigation of atrial fibrillation and inherited cardiac conditions.